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CHAPTER I
INTRODUCTION
Background and Need
Substance use disorders (SUDs) are a rapidly evolving public health crisis. SUDs are
associated with a myriad of adverse consequences including overdose, contraction of infectious
diseases, and development of psychiatric comorbidities such as depression (World Drug Report,
2020). While pharmacotherapies exist for certain SUDs, most current medications require daily
adherence to self-administration, and long-term abstinence rate remain low (Mattick et al., 2001).
Additionally, there are currently no FDA-approved medications to treat stimulant use disorders
(such as cocaine, amphetamines), benzodiazepine use disorder and cannabis use disorder.
Consequently, there is a clear need for novel, efficacious pharmacotherapies for treatment of SUDs.
Multiple prior studies including both randomized controlled trials and naturalistic studies
suggest that medications known as psychedelics have potential therapeutic benefit in the treatment
of addictions and other psychiatric disorders. In a dose-dependent manner, this class of compounds
is associated with novel psychoactive experiences characterized by dream-like states, altered
sensory perceptions, and an increased sense of universal connectedness. Psychedelic compounds
are associated with a high safety profile with extremely low levels of morbidity and mortality, and
limited evidence of any physical dependence (Johnson et al., 2018; Nichols, 2016).
Investigational study using these compounds for the treatment of mental health disorders
has escalated in the past decade. Psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA)
have been particularly well studied, and in the past three years, the FDA granted “breakthrough
therapy” designation to these medications for treatment resistant depression and post-traumatic
stress disorder (PTSD), respectively. While these medications are considered somewhat
controversial due to their unique psychoactive effects, a previous national level survey of the
general population found that a majority of Americans supported research and potentially clinical
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use of these medications for mental health disorders. Despite increasing evidence of efficacy in
SUD treatment however, no prior study has investigated whether individuals with SUDs would be
open to treatment with these new therapeutic agents. My hypothesis was that individuals with a
SUD would demonstrate differential acceptance of these treatment modalities as a function of prior
awareness of these medications.
Problem Statement
Although psychedelic medications appear efficacious in SUD treatment, no prior study has
investigated whether individuals with SUDs would be open to treatment with this class of
medications. Further, while prior clinical trials have been conducted using various psychedelics to
treat patients with a SUD, individuals already involved in psychedelic therapy research may not
display the same attitudes and opinions with SUD individuals who have not received these
therapies.
Innovation
Collectively, the analyses provide critical insights into patient-perspectives on the use of
these novel psychotherapeutics for the treatment of SUDs. This study had the advantage of utilizing
previously completed nationwide survey data in a large population (N=920). Furthermore, this
study provides essential information that will direct future research recruitment efforts and clinical
considerations using these treatments and will inform future studies for this urgent public health
need.

CHAPTER II
REVIEW OF THE LITERATURE
Substance use disorders (SUDs) are a rapidly evolving public health issue
SUDs affect an estimated 35.6 million individuals worldwide (World Drug Report, 2020).
SUDs can lead to many adverse clinical consequences including contraction of infectious diseases,
2

overdose, and the development of comorbid psychiatric disorders (World Drug Report, 2020).
SUDs are classified on a range from mild to moderate to severe, with severity being dependent on
how many criteria are met according to the Diagnostic and Statistical Manual of Mental Disorders
(DSM). Criteria include physiologic changes (i.e. craving, tolerance, and withdrawal symptoms),
psychosocial problems (i.e. legal issues, occupational impairment, use in hazardous situations,
decreased recreational enjoyment, family or social problems), and use despite harms to mental or
physical well-being.
Addiction is generally characterized as a recurring cycle of binging/intoxication,
withdrawal/negative affect, and preoccupation/anticipation also known as “craving” (Koob et al.,
2016). This cycle worsens over time and involves changes in reward, stress, and executive function
systems in the brain (Koob et al., 2016). Additionally, changes in brain activity associated with a
mental illness, may increase an individual’s risk to abuse substances by enhancing the drug’s
rewarding effects, reducing awareness of negative effects, and/or alleviating unpleasant symptoms
of the mental disorder or the side effects of the medication used to treat it (NIDA, 2020).
When a drug of abuse is taken, origins and terminal areas of the ascending
mesocorticostriatal dopamine systems are activated, largely contributing to the rewarding
properties of these substances (Koob et al., 2016). When drugs of abuse are taken at doses
producing intoxication, there is a fast and profound release of dopamine into the ventral striatum
which binds and activates dopamine D1 receptors, producing the rewarding effects and triggering
conditioned responses to the stimulus (Koob et al., 2016). Understanding changes at the molecular,
cellular, and neurocircuitry levels that allow for the transition from an occasional substance user to
a chronic substance user who suffers from loss of control in their drug intake is critical for the
treatment of SUDs (Koob et al., 2016). Knowledge of relevant brain circuits, neurotransmitters,
and neuromodulators has evolved substantially over the years and now include y-aminobutyric acid
(GABA), glutamate, serotonin, acetylcholine, and endocannabinoid systems (Koob et al., 2016).
3

Substances of abuse work via neurotransmitter-specific neuroplasticity circuits in order to
rewire executive function circuits, motivational circuits, and stress circuits resulting in poor
inhibitory control and decision making (Koob et al., 2016). It is this rewiring that can lead to a once
neutral stimuli now being associated with positive reward commonly referred to as reinforcement
(Koob et al., 2016). When reinforcement occurs, it strengthens the rewiring of these
neurotransmitter-specific reward circuits, making it much harder to stop using the drug and the
motivation to binge again even greater. Furthermore, this repeated cycle of binging to intoxication
and subsequent strengthening of reward circuits leads to the development of tolerance for the drug
at the current dose being taken.
When tolerance occurs, a larger dose of the drug of abuse must be taken in order to achieve
the same rewarding effects once felt previously, substantially increasing one’s risk of overdose.
Prior brain imaging studies have shown amphetamine/methylphenidate-induced striatal dopamine
responses are 50% lower in detoxified users compared to an 80% lower response in active abusers
(Koob et al., 2016). While experiencing drug tolerance, if the individual does not take a larger dose
of the drug of abuse, they will begin to experience the withdrawal stage of addiction.
The withdrawal stage consists of several negative affects including increased stress,
irritability, malaise, and even emotional pain (Koob et al., 2016). This is largely due to the
recruitment of key brain stress systems such as corticotropin releasing factor (CRF),
norepinephrine, and dynorphin to the amygdala (Koob et al., 2016). This decrease in reward and
increase in stress function results in craving which drives the individual to compulsively seek out
more of the drug, potentially engaging in risky activities to do so (Koob et al., 2016). These cravings
are largely influenced by cues the individual has come to associate with the drug of abuse. Cues
may vary widely from person to person, but can include a certain time of day, a particular room in
the house, the sight of drug paraphernalia, etc. These cues that the individual has come to associate
with the drug of abuse lead to a dopamine release in the striatum, amygdala, and prefrontal cortex
4

along with opioid peptide release in the anterior cingulate and frontal cortex (Koob et al., 2016),
fueling the individual’s craving.
Current therapies for SUDs are inadequate and novel treatments are needed
There are currently several medications for SUDs on the market today which have been
granted FDA approval. These include pharmacotherapies for tobacco use disorder, alcohol use
disorder and opioid use disorder. While these SUDs can be treated with medications, many existing
pharmacotherapies require daily adherence to medication self-administration, and long-term
abstinence rates remain low (Mattick et al., 2001). Additionally, individuals with co-occurring
mental health disorders and substance use disorders report lower rates of treatment success, higher
rates of psychiatric hospitalizations, and a higher prevalence of suicide (World Drug Report, 2020).
It has been shown that only 18 % of addiction treatment programs and 9 % of mental health
programs were able to provide pertinent treatment to dual diagnosis individuals in the United States
(McGovern et al., 2014).
In the case of opioid use disorder, there are currently only 3 main FDA approved
medications authorized for treatment, naltrexone, methadone, and buprenorphine - naloxone.
Treatment with methadone may be used short-term in order to detoxify patients from opioids,
however, it is also commonly used in long-term treatment provided the individual attends
mandatory counseling due to the risks involved with methadone treatment (Butelman et al., 2017).
Methadone can be fatal if taken in overdose and may also increase one’s risk of severe liver disease
with paired use of other substances such as alcohol or psychotropic medications like
benzodiazepines and barbiturates (Kreek, Oratz, & Rothschild, 1978).
The opioid partial agonist medication, buprenorphine - naloxone, has a lower risk or
overdose than methadone due to its ceiling effect on respiratory depression (Butelman et al., 2017).
Drug counseling is highly recommended for treatment and patients must be seen at frequent
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intervals until a stable dosage is achieved (Butelman et al., 2017). This can lead to a significant
reduction in long term abstinence rates due to patient drop out. Additionally, current FDA approved
medications to treat alcohol and tobacco use disorders require daily medication self-administration,
sometimes multiple times a day, further contributing to low long-term abstinence rates for these
SUDs. Moreover, there are currently no FDA-approved medications to treat stimulant use disorders
(such as cocaine and amphetamines), benzodiazepine use disorder, or cannabis use disorder.
Collectively, this demonstrates a substantial need for novel, efficacious pharmacotherapies for
treatment of SUDs.
Novel psychoactive medications may improve ability to maintain abstinence across a
broad variety of SUDs
A class of compounds with unique psychoactive effects called psychedelics, have shown
early evidence of efficacy in the treatment of substance use disorders. In a dose dependent fashion,
psychedelic compounds can temporarily produce dream-like states, altered sensory perceptions,
and increased sense of universal connectedness. Unlike most existing SUD pharmacotherapies,
these medications appear to improve ability to maintain abstinence across a wide spectrum of SUDs
and may improve ability to maintain abstinence with only one or a few medication administrations
(Curran et al., 2018). Evidence demonstrates that psychedelics have a high safety profile with
extremely low levels of morbidity and mortality, and studies show limited evidence of any physical
dependence

(Johnson

et

al.,

2018;

Nichols,

2016).

Psilocybin

and

3,4-

Methylenedioxymethamphetamine (MDMA) have been particularly well studied, and in the past
three years, the FDA granted “breakthrough therapy” designation to these medications for treatment
resistant depression and post-traumatic stress disorder (PTSD), respectively. Breakthrough therapy
is granted when preliminary clinical data indicates that a drug intended to treat a serious medical
condition has demonstrated substantial improvement over the currently available therapies
(Commissioner, O., 2018).
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Psilocybin is a naturally occurring psychedelic produced in a variety of mushrooms.
Psilocybin broken down to its pharmacologically activated form, psilocin, in the gastrointestinal
tract and kidneys (Psilocybin, 2016). Once converted to psilocin, it acts as a high-affinity agonist
at several serotonin 5-HT receptors (Psilocybin, 2016). The most common of these being 5-HT2A
receptors which are especially prominent in the prefrontal cortex, resulting in increased cortical
activity (Psilocybin, 2016). Due to dysfunction in the monoamine systems of serotonin (5-HT) seen
in SUDs (Bas et al. 2017), psilocin’s action on the serotonergic pathway makes psilocybin a key
drug of interest for the treatment of SUDs.
Psilocybin has demonstrated efficacy in the treatment of tobacco use disorder with 80% of
participants showing seven-day point prevalence abstinence at 6th month follow-up (Johnson et al.,
2014). A study on alcohol use disorder showed that participants reporting heavy drinking days 40%
of the time at baseline were able to reduce heavy drinking days to <20% after just one or two
treatment sessions (Bogenschutz et al., 2015). Furthermore, a study investigating treatmentresistant depression found that one week after 2 sessions, 71% of participants had >50% reduction
in depression severity and 58% were completely in remission (Davis et al., 2020).
Ketamine is a racemic mixture of two enantiomers, esketamine (S-Ketamine) and
arketamin (R-Ketamine) (Himmelseher et al. 2008). Ketamine first gained FDA approval in 1970
for its human use as an anesthetic (Jansen, 2000). Much research has gone into Ketamine since and
it has shown great promise in the treatment of SUDs. A previous study demonstrated that after 3
treatments with ketamine combined with therapy, 50% of study participants were able to abstain
from using heroin fully for over 1 year (Jones et al., 2018). In a related study with heavy alcohol
users, it was discovered that nearly 2/3 of participants were able to maintain abstinence for over
one year after a single session of ketamine in conjunction with psychotherapy (Jones et al., 2018).
Furthermore, several other recent trials in cocaine users have shown that motivation to quit
increases following a ketamine treatment. (Jones et al., 2018).
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Additional studies have demonstrated an anti-depressant effect when participants were
given sub-anesthetic doses of ketamine, leading to ultra-rapid remission of severe depression
symptoms including thoughts of suicide (Jones et al., 2018). This anti-depressant effect is
hypothesized to be mediated by ketamine’s action as an NMDA receptor (NMDAR) antagonist
(Strasburger et al., 2017). Antagonism of the NMDAR by Ketamine was hypothesized to increase
overall activity in the prefrontal cortex due to NMDAR inhibition expressed on GABAergic
interneurons (Zanos et al., 2018). This increase in activity produces various synaptic improvements
including structural increase of spine densities at synaptic proteins, ultimately hypothesized to
improve one’s ability to learn new behaviors which may prove to be invaluable in the treatment of
SUDs (Jones et al. 2018).
3,4-Methylenedioxymethamphetamine (MDMA) acts as an indirect serotonin agonist,
acting on the serotonin transporter where it is then transported to the nerve terminal (Baker et al.
2004). Being inside the terminal affects the amount of serotonin which can be stored within vesicles
and thus leads to a significant increase in serotonin release into the synapse (Baker et al. 2004).
Additionally, MDMA increases release of dopamine and noradrenaline in what is believed to be a
similar manner (Baker at al., 2004). In 2016, the FDA approved MDMA for phase 3 clinical trials
as a treatment for post-traumatic stress disorder (PTSD), which is a condition that commonly occurs
alongside addictions. A prior study from 2012 demonstrated that with 3 doses of MDMA
administered under a psychiatrist's guidance, the patients reported a 56% decrease of severity of
symptoms on average, and 66% no longer met the criteria for having PTSD by the end of the study
with improvements lasting more than a year after therapy (Mithoefer et al., 2012).
Target population support for psychedelic treatments is unknown
Previous work has shown strong overall public support for research into this medication
class (McCarriston, 2017). In a 2017 national survey of the general population, 53% of all
respondents supported medical research into psychedelic drugs. A majority (63%) also said they
8

would personally be open to medical treatment with psilocybin, ketamine, or MDMA if they had a
medical condition for which it was proven effective and safe (McCarriston, 2017). However, it is
unknown whether individuals with SUDs have similar levels of support. A majority of individuals
with SUDs will have tried more than one addictive substance, which suggests that they may have
previously tried psychedelic compounds (McCance-Katz, 2019).

However, SUDs are also

characterized by avoidant thought processes however, and individuals often report using substances
to cope with difficult feelings.
Given that psychedelic compounds can be associated with challenging psychoactive
experiences, it is thus unclear whether individuals with SUDs will endorse a similar level of support
to the general population, or whether they will endorse particular concerns about these prospective
new treatment modalities.

CHAPTER III
METHODOLOGY
Research Design
A cross-sectional survey study was designed and administered in order to analyze patientperspectives on the use of these novel psychotherapeutics for the treatment of SUDs. Prior to
completion of the main survey, potential participants were required to first complete a pre-screener
questionnaire. This questionnaire evaluated several criteria for SUDs in order to ensure that only
those self-reporting criteria matching that of a SUD would be offered the opportunity to complete
the full survey. IP constraints were set up to prevent participants from taking the survey more than
once.
Recruitment
Recruitment was conducted primarily through advertisements placed on the internet (i.e.
Craigslist). Both pre-screening and the survey were conducted using the secure web database,
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REDCap. REDCap is primed to support online and offline data capture for research studies and
operations.
Inclusion Criteria
To have been considered for inclusion in the study, participants must have been (1) over
the age of 18, of any gender, race or ethnicity, (2) able to comprehend English, (3) able to provide
informed consent and function at an intellectual level sufficient to allow accurate completion of the
assessment instruments, (4) self-reporting at least 2 criteria for SUD, and (5) have used a substance
of abuse at least once in the past month.
Exclusion Criteria
Potential participants were excluded if they (1) did not self-reporting at least 2 criteria for
a SUD, (2) did not report using a substance of abuse at least once per month, (3) denied ever
wanting to cut back on or stop using a substance of abuse, or (4) did not give their informed consent
to participate in the study.
Screening and Informed Consent
Initial screening eligibility using the inclusion and exclusion criteria was conducted using
a pre-screener questionnaire hosted via REDCap. Participants were informed that participation in
the study was voluntary, and they could discontinue at any time. Participants were provided with
an overview of the study procedures in advance.
Assessment Procedures
Following completion of informed consent, and provided that all inclusion and exclusion
criteria were satisfied, eligible participants proceeded to take the “Opinions on Psychedelic
Therapy” main survey. The survey took approximately 20 minutes to complete. The survey was
anonymous, but participants were asked basic questions about themselves such as their age, gender,
10

race, and use of alcohol and various substances. Participants went on to answer questions regarding
(1) their level of support for the psychotherapeutics psilocybin, ketamine and MDMA being used
in medical trials, (2) whether or not they believe these psychotherapeutics could be a beneficial
treatment for people suffering with addictions, and (3) whether or not they themselves would be
willing to participate in one of these trials. The psychotherapeutics psilocybin, ketamine, and
MDMA were specifically chosen to asses individual level of support as there have been multiple
prior studies conducted which demonstrate their efficacy in the treatment of addictions and other
psychiatric disorders and thus they would be most likely to continue to be used in future medical
trials.
Participants were then asked to select from a list of 14 concerns regarding the use of
psychedelics (psilocybin, ketamine, MDMA, or other psychedelic medications) to reduce or stop
using alcohol or other drugs. The concerns listed were comprised of common fears that are
associated with perceived possible consequences that might arise from taking a psychotherapeutic
(fear of a bad trip, fear of losing one’s mind, fear of job loss, etc.). Participants could select any
number of concerns from this list or a “N/A” option if they had no concerns.
Participant Compensation
Participants were eligible to be compensated for their time with a $15 Amazon gift card.
This gift card would be sent to their email address. If the participant did not wish to provide their
email address, they may still take the survey, but they would not be able to receive compensation.
Data Analytic Procedure
All data from this survey was collected and managed using the secure REDCap (Research
Electronic Data Capture) database. Furthermore, all data was analyzed using the SPSS statistical
software platform. Baseline demographic characteristics were collected from all participants and
descriptive statistics for the sample population were analyzed.
11

Research Questions and Hypotheses
AIM 1
To determine acceptance rates of the use of psychedelics as a therapeutic modality among
individuals self-reporting SUDs. Based on previous studies which suggest that higher levels of
education are associated with increased levels of acceptance of these new treatments in the general
population, I hypothesized that prior knowledge of these treatment modalities would have the
greatest impact on the level of support for these treatments. To test this hypothesis, we quantified
the level of support for the use of psilocybin, ketamine, and MDMA as a function of prior
knowledge of these psychedelic medications. Taken together, these data detail the role of how
public awareness of these novel treatments modulates the support for their use in research and
clinical contexts.
To test this hypothesis, the independent variable assessed was between prior psychedelic
knowledge individuals and no prior psychedelic knowledge individuals. The dependent variable
was characterized by the level of psychedelic support expressed between the two groups based on
each individual’s ranked choices regarding the use of psychedelics in medical research. This was
accomplished through use of Mann-Whitney U.
AIM 2
To characterize concerns about the therapeutic use of psychedelics among individuals selfreporting SUDs. Given that these medications have unique psychoactive effects, I hypothesized
that the number of concerns regarding the therapeutic use of psychedelics would be greatest in
individuals who have never used psychedelics previously in contrast to those who had. We further
explored whether prior use affects the type of concerns expressed. My prediction was that
individuals not reporting prior use would be more likely to endorse concerns related to the
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experience itself (i.e. fear of "going crazy") and that there would be no difference between groups
on psychosocial concerns (i.e. fear of judgement from family).
To test this hypothesis, the independent variable assessed was between prior psychedelic
use individuals and no prior psychedelic use individuals. The dependent variable was characterized
by number of psychedelic concerns expressed between the two groups and which groups
demonstrated greater or fewer concerns. This was accomplished through use of Mann-Whitney U.
Exploratory Hypothesis
Acceptance rates for the use of psychotherapeutics will directly correlate with discrete
concerns about the therapeutic use of these compounds. To test this hypothesis, the first
independent variable assessed was between individuals who support medical trials with psilocybin,
ketamine and MDMA and individuals who do not. An additional independent variable was
characterized by whether individuals in each group had discrete concerns regarding psychedelic
use. This was accomplished through use of a nominal regression.
Bias, Problems and Alternative Strategies
While the secondary analysis of existing data is widely accepted and well-validated for
research purposes, its use of previously collected data is subject to bias and confounding as
researchers must decide what variables to use when the outcomes are known (Penson, 2006).
Confounding occurs when a differential distribution of unmeasured variables exists among the
samples used to create a secondary dataset and can cause associations to exist when there are none
(Penson, 2006). Design variables used in the study were applied in the analysis in order to remove
bias. Confounding was controlled through the utilization of random samples.

CHAPTER IV
ARTICLE MANUSCRIPT
Abstract
13

Substance use disorders (SUDs) present a rapidly evolving public health crisis and many
individuals with SUDs fail to maintain abstinence despite adherence to current standard of care
treatment options. Prior research has demonstrated compounds with unique psychoactive properties
may improve ability to maintain abstinence across a variety of SUDs; examples of such compounds
include psilocybin, ketamine, and 3,4-Methylenedioxymethamphetamine (MDMA). However,
target population support for mental health treatment using these medications is unknown. In this
study, a cross-sectional survey (n=919) was administered to analyze patient-level perspectives on
the use of these novel psychotherapeutics for the treatment of SUDs. We hypothesized that
individuals with SUDs would demonstrate differential acceptance of these treatment modalities as
a function of prior awareness of these medications. The results showed that the majority of survey
participants supported medical trials being conducted with psilocybin (72.1%), ketamine (71.6%),
and MDMA (68.1%) in the future. Furthermore, survey respondents with prior knowledge of
ketamine as a potential treatment option were significantly more in support of clinical trial research
with ketamine compared to individuals without such prior awareness (3.96 vs 3.79; p= .005).
However, there was no statistically significant difference in support for future research into
psilocybin or MDMA based on prior knowledge of these potential treatment modalities. These
results can be used to direct future research recruitment efforts and provide insight into clinical
considerations that should be made when using these treatments.

Introduction
Substance use disorders (SUDs) are a rapidly evolving public health crisis. SUDs can lead
to many adverse clinical consequences including contraction of infectious diseases, overdose, and
the development of comorbid psychiatric disorders (World Drug Report, 2020). SUDs are classified
on a range from mild to moderate to severe, with severity being dependent on how many criteria
are met according to the Diagnostic and Statistical Manual of Mental Disorders (DSM). Criteria
include physiologic changes (i.e. craving, tolerance, and withdrawal symptoms), psychosocial
14

problems (i.e. legal issues, occupational impairment, use in hazardous situations, decreased
recreational enjoyment, family or social problems), and use despite harms to mental or physical
well-being.
There are currently several medications for SUDs on the market today which have been
granted FDA approval. These include pharmacotherapies for tobacco use disorder (TUD), alcohol
use disorder (AUD) and opioid use disorder (OUD). While these SUDs can be treated with
medications, many existing pharmacotherapies require daily adherence to medication selfadministration, and long-term abstinence rates remain low (Mattick et al., 2001). In the case of
OUD, there are currently only 2 main FDA approved medications authorized for treatment,
methadone, or buprenorphine/naloxone (Subutex) (Butelman et al., 2017). Treatment with
methadone may be used short-term in order to detoxify patients from opioids, however, it is also
commonly used in long-term treatment provided the individual attends mandatory counseling due
to the risks involved with methadone treatment (Butelman et al., 2017). Methadone can be fatal if
taken in overdose and may also increase one’s risk of severe liver disease with paired use of other
substances such as alcohol or psychotropic medications like benzodiazepines and barbiturates
(Kreek, Oratz, & Rothschild, 1978).
The opioid partial agonist medication, buprenorphine/naloxone (Subutex), has a lower risk
or overdose than methadone due to its ceiling effect on respiratory depression (Butelman et al.,
2017). Drug counseling is mandatory for treatment and patients must be seen at frequent intervals
until a stable dosage is achieved (Butelman et al., 2017). This can lead to a significant reduction in
long term abstinence rates due to patient drop out. Furthermore, individuals with co-occurring
mental health disorders and substance use disorders report lower rates of treatment success, higher
rates of psychiatric hospitalizations, and a higher prevalence of suicide (World Drug Report, 2020).
It has been shown that only 18 % of addiction treatment programs and 9 % of mental health
programs were able to provide pertinent treatment to dual diagnosis individuals in the United States
15

(McGovern et al., 2014). Additionally, there are currently no FDA-approved medications to treat
stimulant use disorders (such as cocaine and amphetamines), benzodiazepine use disorder, or
cannabis use disorder.
Novel psychoactive medications may improve ability to maintain abstinence across a broad
variety of SUDs. A class of compounds with unique psychoactive effects called psychedelics, have
shown early evidence of efficacy in the treatment of substance use disorders. In a dose dependent
fashion, psychedelic compounds can temporarily produce dream-like states, altered sensory
perceptions, and increased sense of universal connectedness.

Unlike most existing SUD

pharmacotherapies, these medications appear to improve ability to maintain abstinence across a
wide spectrum of SUDs and may improve ability to maintain abstinence with only one or a few
medication administrations (Curran et al., 2018). Evidence demonstrates that psychedelics have a
high safety profile with extremely low levels of morbidity and mortality, and studies show limited
evidence of any physical dependence (Johnson et al., 2018; Nichols, 2016). Psilocybin and 3,4Methylenedioxymethamphetamine (MDMA) have been particularly well studied, and in the past
three years, the FDA granted “breakthrough therapy” designation to these medications for treatment
resistant depression and post-traumatic stress disorder (PTSD), respectively. Breakthrough therapy
is granted when preliminary clinical data indicates that a drug intended to treat a serious medical
condition has demonstrated substantial improvement over the currently available therapies
(Commissioner, O., 2018).
Previous work has shown strong overall public support for research into this medication
class (McCarriston, 2017). In a 2017 national survey of the general population, 53% of all
respondents supported medical research into psychedelic drugs. A majority (63%) also said they
would personally be open to medical treatment with psilocybin, ketamine, or MDMA if they had a
medical condition for which it was proven effective and safe (McCarriston, 2017). However, it is
unknown whether individuals with SUDs have similar levels of support. A majority of individuals
16

with SUDs will have tried more than one addictive substance, which suggests that they may have
previously tried psychedelic compounds (McCance-Katz, 2019).

However, SUDs are also

characterized by avoidant thought processes however, and individuals often report using substances
to cope with difficult feelings.
Given that psychedelic compounds can be associated with challenging psychoactive
experiences, it is thus unclear whether individuals with SUDs will endorse a similar level of support
to the general population, or whether they will endorse particular concerns about these prospective
new treatment modalities.

Methods
Study Design and Recruitment
A cross-sectional survey study was designed and administered to 932 participants in order
to analyze patient-level perspectives on the use of these novel psychotherapeutics for the treatment
of SUDs. 12 participants did not complete the survey. Prior to completion of the main survey,
potential participants were required to first complete a pre-screener questionnaire.

This

questionnaire evaluated several criteria for SUDs in order to ensure that only those self-reporting
criteria matching that of a SUD would be offered the opportunity to complete the full survey. IP
constraints were set up to prevent participants from taking the survey more than once.
Recruitment was conducted primarily through advertisements placed on the internet (i.e.
Craigslist). Both pre-screening and the survey were conducted using the secure web database,
REDCap. REDCap is primed to support online and offline data capture for research studies and
operations. To have been considered for inclusion in the study, participants must have been (1) over
the age of 18, of any gender, race or ethnicity, (2) able to comprehend English, (3) able to provide
informed consent and function at an intellectual level sufficient to allow accurate completion of the
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assessment instruments, (4) self-reporting at least 2 criteria for SUD, and (5) have used a substance
of abuse at least once in the past month.
Screening and Informed Consent
Initial screening eligibility using the inclusion and exclusion criteria was conducted using
a pre-screener questionnaire hosted via REDCap. Participants were informed that participation in
the study was voluntary, and they could discontinue at any time. Participants were provided with
an overview of the study procedures in advance.
Assessment Procedures
Following completion of informed consent, and provided that all inclusion and exclusion
criteria were satisfied, eligible participants proceeded to take the “Opinions on Psychedelic
Therapy” main survey. The survey took approximately 20 minutes to complete. The survey was
anonymous, but participants were asked basic questions about themselves such as their age, gender,
race, and use of alcohol and various substances. Participants went on to answer questions regarding
(1) their level of support for the psychotherapeutics psilocybin, ketamine and MDMA being used
in medical trials, (2) whether or not they believe these psychotherapeutics could be a beneficial
treatment for people suffering with addictions, and (3) whether or not they themselves would be
willing to participate in one of these trials. The psychotherapeutics psilocybin, ketamine, and
MDMA were specifically chosen to asses individual level of support as there have been multiple
prior studies conducted which demonstrate their efficacy in the treatment of addictions and other
psychiatric disorders and thus they would be most likely to continue to be used in future medical
trials.
Participants were then asked to select from a list of 14 concerns regarding the use of
psychedelics (psilocybin, ketamine, MDMA, or other psychedelic medications) to reduce or stop
using alcohol or other drugs. The concerns listed were comprised of common fears that are
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associated with perceived possible consequences that might arise from taking a psychotherapeutic
(fear of a bad trip, fear of losing one’s mind, fear of job loss, etc.). Participants could select any
number of concerns from this list or a “N/A” option if they had no concerns.
Participant Compensation
Participants were eligible to be compensated for their time with a $15 Amazon gift card.
This gift card would be sent to their email address. If the participant did not wish to provide their
email address, they may still take the survey, but they would not be able to receive compensation.
Data Analytic Procedure
All data from this survey was collected and managed using the secure REDCap (Research
Electronic Data Capture) database. Furthermore, all data was analyzed using the SPSS statistical
software platform. This study had the advantage of utilizing previously completed nationwide
survey data in a large population (N=920). Baseline demographic characteristics were collected
from all participants and descriptive statistics for the sample population were analyzed (Table 1).
While the secondary analysis of existing data is widely accepted and well-validated for
research purposes, its use of previously collected data is subject to bias and confounding as
researchers must decide what variables to use when the outcomes are known (Penson, 2006).
Confounding occurs when a differential distribution of unmeasured variables exists among the
samples used to create a secondary dataset and can cause associations to exist when there are none
(Penson, 2006). Design variables used in the study were applied in the analysis in order to remove
bias. Confounding was controlled through the utilization of random samples.

Results
Of the 920 individuals who completed the survey, 919 questionnaires were included in the
study as one participant did not complete questions regarding their prior use of psychedelics. Our
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research found the overall majority of survey participants supported medical trials being conducted
with psilocybin (72.1%), ketamine (71.6%), and MDMA (68.1%) in the future (Table 2a-c; Figure
1a-c). To further determine acceptance rates of the use of psychedelics as a therapeutic modality
among individuals self-reporting SUDs, we quantified the level of support for the use of psilocybin,
ketamine and MDMA as a function of prior knowledge of these psychedelic medications. It was
hypothesized that prior knowledge of these treatment modalities would have the greatest impact on
the level of support for these treatments.
To test this hypothesis, the independent variable assessed was between prior psychedelic
knowledge individuals and no prior psychedelic knowledge individuals. The dependent variable
was characterized by the level of psychedelic support expressed between the two groups based on
each individual’s ranked choices regarding the use of psychedelics in medical research. This was
accomplished through use of Mann-Whitney U due to a non-normal data distribution. Ketamine
support scores were significant between participants with versus participants without prior
awareness (3.96 vs 3.79; p=.005) (Table 3; Figure 2c-d), but there was no statistically significant
difference regarding psilocybin or MDMA.
In addition, we were interested to characterize concerns about the therapeutic use of
psychedelics among individuals self-reporting SUDs. Given that these medications have unique
psychoactive effects, it was hypothesized that the number of concerns regarding the therapeutic use
of psychedelics would be greatest in individuals who have never used psychedelics previously in
contrast to those who had. It was further explored whether prior use affects the type of concerns
expressed. The prediction was that individuals not reporting prior use would be more likely to
endorse concerns related to the experience itself (i.e. fear of "going crazy") and that there would be
no difference between groups on psychosocial concerns (i.e. fear of judgement from family).
To test this hypothesis, the independent variable assessed was between prior psychedelic
use individuals and no prior psychedelic use individuals. The dependent variable was characterized
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by total number of psychedelic concerns expressed between the two groups and which groups
demonstrated greater or fewer concerns. This was accomplished through use of Mann-Whitney U
due to a non-normal data distribution. There was no statistically significant difference found
between an individual’s prior psychedelics use and overall concerns, having concerns related to the
experience itself, nor a difference between groups regarding psychosocial concerns (Figure 3a-c).
Additionally, our group went on to explore whether acceptance rates for the use of
psychotherapeutics would directly associate with discrete concerns about the therapeutic use of
these compounds. To test this, the first independent variable assessed was between individuals who
support medical trials with psilocybin, ketamine and MDMA and individuals who do not. An
additional independent variable was characterized by whether individuals in each group had
discrete concerns regarding psychedelic use. This was accomplished using nominal regression.
For psilocybin, one concern was identified to be significantly correlated with an
individual’s level of support for medical trials being conducted with psilocybin in the future. For
each unit of support increased, the odds of not selecting the concern “Fear that you would lose your
sense of self” increased by 1.299 (95% CI, 1.063 to 1.588) times, a statistically significant effect,
p = .011 (Table 5a). For Ketamine, two concerns were identified to be significantly correlated with
an individual’s level of support for trying ketamine treatment themselves. For each unit of support
increased, the odds of not selecting the concern “Fear that it would change you” increased by 1.207
(95% CI, 1.009 to 1.444) times, a statistically significant effect, p = .039 (Table 5b). For each unit
of support increased, the odds of not selecting the concern “Fear that you would harm yourself or
others while on a bad trip” increased by 1.211 (95% CI, 1.009 to 1.453) times, a statistically
significant effect, p = .040 (Table 5b). Additionally, one concern was significantly correlated with
an individual’s level of support for ketamine treatment being beneficial for people with SUDs. For
each unit of support increased, the odds of not selecting the concern “Fear that you would feel guilt
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during your trip” increased by 1.233 (95% CI, 1.014 to 1.500) times, a statistically significant
effect, p = .035 (Table 5b).
For MDMA, two concerns were identified to be significantly correlated with an
individual’s level of support for medical trials with MDMA being conducted in the future. For each
unit of support reduction, the odds of not selecting the concern “Fear that it would cause you to "go
crazy" or "lose your mind”” increased by 0.774 (95% CI, 0.648 to 0.925) times, a statistically
significant effect, p = .005 (Table 5c). For each unit of support reduction, the odds of not selecting
the concern “Fear that you would harm yourself or others while on a bad trip” increased by 0.791
(95% CI, 0.658 to 0.951) times, a statistically significant effect, p = .013 (Table 5c). Two additional
concerns were identified to be significantly correlated with an individual’s level of support for
MDMA being beneficial for people with a SUD. For each unit of support reduction, the odds of not
selecting the concern “Fear that you would lose your sense of self” increased by 0.749 (95% CI,
0.618 to 0.908) times, a statistically significant effect, p = .003 (Table 5c). For each unit of support
reduction, the odds of not selecting the concern “Fear that it would affect your employment”
increased by 0.770 (95% CI, 0.630 to 0.941) times, a statistically significant effect, p = .011 (Table
5c). Finally, two concerns were identified to be significantly correlated with an individual’s level
of support for trying MDMA themselves if treatment was appropriate. For each unit of support
reduction, the odds of not selecting the concern “Fear that you would feel guilt during your trip”
increased by 0.843 (95% CI, 0.740 to 0.960) times, a statistically significant effect, p = .010 (Table
5c). For each unit of support reduction, the odds of not selecting the concern “Fear that it would
affect your employment” increased by 0.862 (95% CI, 0.751 to 0.990) times, a statistically
significant effect, p = .036 (Table 5c).
Discussion
There is a clear need for novel, efficacious pharmacotherapies for treatment of SUDs.
While pharmacotherapies exist for certain SUDs, most current medications require daily adherence
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to self-administration, and long-term abstinence rate remain low. Additionally, there are currently
no FDA-approved medications to treat stimulant use disorders (such as cocaine, amphetamines),
benzodiazepine use disorder and cannabis use disorder. Multiple prior studies including both
randomized controlled trials and naturalistic studies suggest that these psychotherapeutic
medications have potential therapeutic benefit in the treatment of addictions and other psychiatric
disorders. These compounds are associated with a high safety profile with extremely low levels of
morbidity and mortality, and limited evidence of any physical dependence.
A 2017 national survey of the general population by the data analytic group, YouGov,
found that the majority of respondents supported future medical research into psilocybin (63%),
ketamine (61%), and MDMA (61%) (McCarriston, 2017). A majority (63%) also said they would
personally be open to medical treatment with psilocybin, ketamine, or MDMA if they had a medical
condition for which it was proven effective and safe (McCarriston, 2017).
Until now it had been unknown whether individuals with SUDs would demonstrate similar
levels of support. While multiple previous clinical trials have been conducted using psychedelics
in an attempt to treat patients with a SUD, individuals already involved in psychedelic therapy
research may not display the same attitudes and opinions with SUD individuals who have not
received these therapies. This study found that the overall majority of survey participants with a
SUD demonstrated a greater support for medical trials being conducted with psilocybin (72.1%),
ketamine (71.6%), and MDMA (68.1%) in the future as compared to the general population (Table
2a-c; Figure 1a-c). Additionally, it was discovered that the overall majority of survey participants
with a SUD demonstrated a greater support for personally being open to medical treatment with
psilocybin (75.6%), ketamine (74.3%), or MDMA (58.9%) if they had a medical condition for
which it was proven effective and safe as compared to the general population (Table 4a-c; Figure
4a-c). It is important to note that most respondents (87%) in this study reported personal prior use
of psychedelics in the past and more work needs to be done to determine whether this plays a role
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in an individual’s acceptance. Moreover, this study did not investigate whether participants who
had previously tried psychedelics had ever done so in an attempt to self-medicate. Multiple prior
studies have shown that individuals who have used psychedelics to self-medicate for a variety of
mental health disorders in the past, report psychedelics to be more efficacious at treating their
symptoms compared to conventional treatments offered by medical professionals (Mason, N. L.,
& Kuypers, K. P. C. (2018), Hutten NR et al. (2019), Lea, T. et al. (2020)). It would be beneficial
for future research to assess whether support differs with individuals who utilized psychedelics to
self-medicate in the past.
When investigating the impact prior awareness of psychedelic research had on support
levels, it was found that ketamine support scores were significantly different between participants
with versus participants without prior awareness (3.96 vs 3.79; p= .005) (Table 3; Figure 2c-d), but
there was no statistically significant difference regarding psilocybin or MDMA. This difference in
ketamine support scores could be explained by the fact that ketamine does not fall into the category
of classic psychedelic and is more well-known for its dissociative properties. While statistical
significance regarding ketamine support was reached, it is argued that a difference in support score
of 3.96 vs 3.79 still demonstrates an overall acceptance of future research with or without prior
awareness.
It was further investigated whether individuals who had indicated prior use of psychedelics
would differ in the number and types of concerns expressed regarding psychedelic therapies from
individuals who had indicated no prior use of psychedelics. The data show there were no significant
differences between prior use vs no prior use groups regarding the number and types of concerns
expressed. While there was no significance reached, this is still beneficial information that can help
direct future research recruitment efforts and clinical considerations using these treatments. Finally,
in an effort to explore whether acceptance rates would directly correlate with discrete concerns
regarding the therapeutic use of psychedelics, it was discovered that there were a handful of
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concerns which significantly affected an individual’s level of support. It is beneficial for future
studies to be aware of how these concerns correlate with individual’s acceptance rates so that an
effort can be made to properly address them and adequately inform the public.
This study provides essential information that will direct future research recruitment efforts
and clinical considerations using these treatments and will inform future studies for this urgent
public health need. There are numerous potential directions that can and should be investigated by
future studies. Investigating how additional key demographics such as age, gender, race, education,
etc. vary with individual levels of support would be an excellent starting point. Additionally, the
majority of participants in this study were poly substance users, meaning they potentially suffered
from multiple SUDs which may have had an impact on acceptance rates. One of the biggest
challenge’s psychedelic research faces today is reversing the stigma that has been placed on these
substances for decades. Future research should be prepared to investigate how political affiliation
affects an individual’s level of support as that information will prove to be extremely vital in
implementing policy change and advancing science and medicine for the benefit of patients.
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Table 1. Participant Demographics
Age
18 to 24
25 to 34
35 to 44
45 to 54
55+
Gender
Male
Female
Transgender or
non-binary
Other or prefer not
to answer
Region
Northeast
Midwest
South
West
Community
Large city
Midsized city
Small city
Suburban
Rural
Education
No high school
Some high school
High school
graduate or have
GED
Some college
Completed twoyear college
degree
Completed fouryear college
degree
Have had some
graduate degree
training
Have completed
graduate degree
training

n (%)
80 (8.7)
447 (48.6)
357 (38.8)
29 (3.2)
6 (0.7)
651 (70.9)
259 (28.2)
4 (0.4)
4 (0.4)
205 (22.3)
210 (22.9)
231 (25.1)
273 (29.7)
406 (44.2)
293 (31.9)
180 (19.6)
35 (3.8)
5 (0.5)
5 (0.5)
12 (1.3)
84 (9.1)
95 (10.3)
218 (23.7)
388 (42.2)
31 (3.4)
86 (9.4)

v

Relationship
Married
Never married
Separated
Divorced
Domestic/civil
partnership
Widowed
Children
Yes
No
Race
White
Black or African
American
Hispanic or Latino
American Indian
or Alaskan Native
Asian
Native Hawaiian
or Pacific Islander
Other or prefer not
to answer
Substance of
abuse
Alcohol
Marijuana
Tobacco
Cocaine
Opiates
Amphetamines
Benzodiazepines
Other
Number of substances used per month
1
2
3
4
>5

619 (67.4)
147 (16.0)
59 (6.4)
44 (4.8)
38 (4.1)
12 (1.3)
646 (70.3)
273 (29.7)
528 (57.5)
191 (20.8)
137 (14.9)
47 (5.1)
26 (2.8)
7 (0.8)
3 (0.3)

569 (61.9)
566 (61.6)
544 (59.2)
234 (25.5)
143 (15.6)
133 (14.5)
112 (12.2)
6 (0.7)
396 (0.43)
126 (0.14)
187 (0.20)
90 (0.10)
120 (0.13)
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Table 2a. Overall Psilocybin Research Level of Support
Based on these preliminary findings, and
anything else you may know: Do you
support or oppose similar medical trials with
psilocybin being conducted in the future?

Strongly
oppose

Frequency

Percent

Valid
Percent

Cumulative
Percent

5

0.5

0.5

0.5

Oppose
Neutral
or
unsure
Support

23

2.5

2.5

3.0

228

24.8

24.8

27.9

432

47.0

47.0

74.9

Strongly
support

231

25.1

25.1

100.0

Total

919

100.0

100.0

Table 2b. Overall Ketamine Research Level of Support
Based on these preliminary findings, and
anything else you may know: Do you
support or oppose similar medical trials with
ketamine being conducted in the future?

Strongly
oppose

Frequency

Percent

Valid
Percent

Cumulative
Percent

5

0.5

0.5

0.5

Oppose
Neutral
or
unsure
Support

44

4.8

4.8

5.3

212

23.1

23.1

28.4

432

47.0

47.0

75.4

Strongly
support

226

24.6

24.6

100.0

Total

919

100.0

100.0
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Table 2c. Overall MDMA Research Level of Support
Based on these findings and what you may
have known previously, do you support or
oppose similar medical trials with MDMA
being conducted in the future?

Strongly
oppose

Frequency

Percent

Valid
Percent

Cumulative
Percent

9

1.0

1.0

1.0

Oppose
Neutral
or
unsure
Support

41

4.5

4.5

5.4

243

26.4

26.4

31.9

387

42.1

42.1

74.0

Strongly
support

239

26.0

26.0

100.0

Total

919

100.0

100.0

Table 3. Prior Awareness vs Research Level of Support
Based on these preliminary
findings, and anything else
you may know: Do you
support or oppose similar
medical trials with psilocybin
being conducted in the
future?
94893.000

Based on these preliminary
findings, and anything else
you may know: Do you
support or oppose similar
medical trials with ketamine
being conducted in the
future?
85426.000

Based on these findings
and what you may have
known previously, do you
support or oppose similar
medical trials with MDMA
being conducted in the
future?
91297.000

MannWhitney
U
Wilcoxon
145296.000
135829.000
141700.000
W
Z
-0.147
-2.802
-1.142
Asymp.
0.883
0.005
0.253
Sig. (2tailed)
a. Grouping Variable: Have you ever previously heard about the use of psychedelic-type substances
(such as psilocybin, LSD, peyote, ibogaine, ayahuasca, and ketamine) being used in the treatment of
addictions?
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Table 4a. Overall Psilocybin “Would Try” Level of Support
If psilocybin is proven to be safe and effective
for the treatment of addictions, would you or
would you not try this treatment if it was
appropriate for you?

Definitely
not

Frequency

Percent

Valid
Percent

Cumulative
Percent

8

0.9

0.9

0.9

Probably
not
Neutral
or
unsure
Probably
would

20

2.2

2.2

3.0

197

21.4

21.4

24.5

404

44.0

44.0

68.4

Definitely
would

290

31.6

31.6

100.0

Total

919

100.0

100.0

Table 4b. Overall Ketamine “Would Try” Level of Support

If ketamine is proven to be safe and effective
for treatment after further trials, would you or
would you not try this treatment if it was
appropriate for you?
Frequency

Percent

Valid
Percent

Cumulative
Percent

Definitely
not

9

1.0

1.0

1.0

Probably
not

36

3.9

3.9

4.9

ix

Neutral
or
unsure
Probably
would

192

20.9

20.9

25.8

403

43.9

43.9

69.6

Definitely
would

279

30.4

30.4

100.0

Total

919

100.0

100.0

Table 4c. Overall MDMA “Would Try” Level of Support
If MDMA is proven to be safe and effective for
treatment after further trials, would you or
would you not try this treatment if it was
appropriate for you?

Definitely
would
Probably
would
Neutral
or
unsure
Probably
would
not
Definitely
would
not
Total

Frequency

Percent

Valid
Percent

Cumulative
Percent

226

24.6

24.6

24.6

315

34.3

34.3

58.9

224

24.4

24.4

83.2

88

9.6

9.6

92.8

66

7.2

7.2

100.0

919

100.0

100.0
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Table 5a. Psilocybin Concerns vs Support

Question:
Concern:

Based on these preliminary findings,
and anything else you may know: Do
you support or oppose similar medical
trials with psilocybin being conducted in
the future?

95% Confidence
Interval for Exp(B)

Std.
B
Error Wald df Sig.
Fear that you would lose your sense of 0.261 0.102 6.519 1 0.011
self

Exp(B)
1.299

Lower
Bound
1.063

Upper
Bound
1.588

Table 5b. Ketamine Concerns vs Support

Question:

Concern:

Question:

Concern:

If ketamine is proven to be
safe and effective for
treatment after further
trials, would you or would
you not try this treatment if
it was appropriate for
you?

B

Std.
Error

Wald

df

Sig.

Exp(B)

95%
Confidence
Interval for
Exp(B)
Lower Upper
Bound Bound

Fear that it would "change
0.188 0.091 4.258
you"

1

0.039 1.207 1.009 1.444

Fear that you would harm
yourself or others while on 0.191 0.093 4.228
a bad trip

1

0.040 1.211 1.009 1.453

Do you think ketamine
could be a beneficial
treatment for people
suffering with addictions?
Fear that you would feel
guilt during your trip

B

Std.
Error

Wald

df

Sig.

Exp(B)

95%
Confidence
Interval for
Exp(B)
Lower Upper
Bound Bound

0.210 0.100 4.424

xi

1

0.035 1.233 1.014 1.500

Table 5c. MDMA Concerns vs Support

Based on these findings and what you may
have known previously, do you support or
oppose similar medical trials with MDMA
being conducted in the future?

B

Std. Error

Wald

df

Sig.

Exp(B)

95% Confidence
Interval for Exp(B)
Lower
Bound

Upper
Bound

Fear that it would cause you to "go crazy" or
-0.256
"lose your mind"

0.091

7.934

1

0.005

0.774

0.648

0.925

Fear that you would harm yourself or others
a
while on a bad trip

0.094

6.214

1

0.013

0.791

0.658

0.951

-0.235

Do you think MDMA could or could not be a
beneficial treatment for people suffering
with PTSD?

B

Fear that you would lose your sense of self

-0.289

0.098

8.697

1

0.003

Fear that it would affect your employment

-0.261

0.102

6.514

1

0.011

Std. Error

Wald

df

Sig.

If MDMA is proven to be safe and effective
for treatment after further trials, would you
or would you not try this treatment if it was
appropriate for you?

B

Fear that you would feel guilt during your
trip

-0.171

0.066

6.626

1

0.010

Fear that it would affect your employment

-0.148

0.071

4.409

1

0.036

Std. Error

xii

Wald

df

Sig.

Exp(B)

95% Confidence
Interval for Exp(B)
Lower
Bound

Upper
Bound

0.749

0.618

0.908

0.770

0.630

0.941

Exp(B)

95% Confidence
Interval for Exp(B)
Lower
Bound

Upper
Bound

0.843

0.740

0.960

0.862

0.751

0.990

Figure 1a. Overall Psilocybin Research Level of Support

Figure 1b. Overall Ketamine Research Level of Support
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Figure 1c. Overall MDMA Research Level of Support

Figure 2a. Psilocybin Research Support vs Prior Awareness
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Figure 2b. Psilocybin Research Support vs No Prior Awareness

Figure 2c. Ketamine Research Support vs Prior Awareness
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Figure 2d. Ketamine Research Support vs No Prior Awareness

Figure 2e. MDMA Research Support vs Prior Awareness
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Figure 2f. MDMA Research Support vs No Prior Awareness
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Figure 3a. Prior Use vs Concerns Overall

xviii

Figure 3b. Prior Use vs Experience Concerns
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Figure 3c. Prior Use vs Psychosocial Concerns
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xxi

Figure 4c. Overall MDMA “Would Try” Level of Support
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